Shingles Vaccine Market Driven by Rising Clinical Recommendations for Older Adults

 

The global shingles vaccine market is experiencing significant growth and is expected to continue its upward trajectory over the next several years. Valued at approximately US$5.7 billion in 2025, the market is projected to reach an impressive US$14.1 billion by 2032, growing at a robust Compound Annual Growth Rate (CAGR) of 13.7%. This growth is driven by a variety of factors, including increasing awareness about the risks of shingles, a rising aging population, and advancements in vaccine technology. This article explores the key trends, growth drivers, challenges, and market opportunities within the global shingles vaccine market.

Overview of Shingles and Its Impact

Shingles, also known as herpes zoster, is a viral infection that causes a painful rash, typically on one side of the body. It is caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in the body and can reactivate later in life, especially in individuals with weakened immune systems or older adults. The condition can cause severe pain, postherpetic neuralgia (a complication that leads to long-term nerve pain), and other serious complications. As the global population ages, the incidence of shingles is expected to increase, making vaccination a crucial preventative measure.

Shingles Vaccine Market Analysis

Market Value and Growth

The shingles vaccine market is currently valued at US$5.7 billion in 2025 and is expected to grow significantly in the coming years. By 2032, the market is anticipated to reach US$14.1 billion, reflecting a CAGR of 13.7% between 2025 and 2032. This growth is driven by several factors, including:

  1. Aging Population: The incidence of shingles increases with age, particularly among individuals aged 50 and older. As the global population ages, there is a greater demand for shingles vaccination.

  2. Rising Awareness: Public awareness campaigns by healthcare providers and governments about the risks and consequences of shingles are encouraging people, particularly those over 50, to seek vaccination.

  3. Advances in Vaccine Technology: Newer vaccines with enhanced efficacy and fewer side effects, such as recombinant vaccines, are driving market growth.

  4. Increasing Healthcare Access: Improved healthcare infrastructure, especially in emerging economies, is facilitating greater access to vaccines.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/33198 

Key Drivers of Market Growth

The shingles vaccine market's growth can be attributed to several factors, including:

  1. Aging Population: The global population is aging, and older adults are more susceptible to shingles. The World Health Organization (WHO) estimates that the number of people over 60 will double by 2050, creating a larger target market for shingles vaccines.

  2. Evolving Vaccine Technologies: Recent advancements in vaccine technology have led to the development of highly effective vaccines like Shingrix, which offer better protection compared to older vaccines. This has helped to increase public confidence in vaccination.

  3. Government Initiatives: In several countries, government programs and insurance reimbursements are encouraging vaccination, particularly for older adults. For example, in the United States, the Centers for Disease Control and Prevention (CDC) recommends shingles vaccination for adults aged 50 and older.

  4. Increased Awareness of Health Risks: Awareness campaigns and educational efforts by public health organizations are playing a key role in informing the public about the risks associated with shingles and the benefits of vaccination.

Market Challenges

Despite the promising growth prospects, the shingles vaccine market faces several challenges:

  1. High Cost: The cost of shingles vaccines, particularly newer vaccines like Shingrix, can be a barrier to widespread adoption, especially in low- and middle-income countries.

  2. Vaccine Hesitancy: Vaccine hesitancy, driven by misinformation and lack of understanding, remains a challenge in some regions. Overcoming skepticism about vaccine safety and efficacy is crucial for increasing vaccination rates.

  3. Regulatory Hurdles: Regulatory approval processes and the requirement for vaccines to undergo rigorous testing before they can be widely distributed may delay the availability of new products in certain regions.

  4. Geographic Disparities in Access: While the vaccine is widely available in developed markets like North America and Europe, access in emerging economies may be limited due to financial, infrastructure, and healthcare system challenges.

Market Segmentation

The shingles vaccine market can be segmented based on product type, vaccine type, distribution channel, and region.

By Product Type

  1. Shingles: This segment includes vaccines specifically designed to prevent shingles, the main driver of the market. These vaccines are essential for reducing the incidence and severity of shingles, particularly in high-risk populations.

  2. Zostavax: Zostavax, a live attenuated vaccine, was one of the first vaccines developed for shingles and is still widely used in some markets. However, newer vaccines, like Shingrix, are gaining market share due to their improved efficacy.

  3. Sky Zoster: A vaccine used in certain regions, Sky Zoster is another live attenuated option, though it faces competition from more advanced alternatives.

By Vaccine Type

  1. Recombinant Vaccine: Recombinant vaccines, such as Shingrix, offer higher efficacy compared to live attenuated vaccines. These vaccines are gaining market dominance due to their superior protection against shingles and their ability to be administered to individuals with weakened immune systems.

  2. Live Attenuated Vaccine: Live attenuated vaccines, such as Zostavax and Sky Zoster, remain popular due to their long history of use. However, their efficacy is lower than that of recombinant vaccines, limiting their growth in the market.

By Distribution Channel

  1. Hospitals: Hospitals are a key distribution channel for shingles vaccines, especially for individuals seeking vaccination as part of a broader healthcare service.

  2. Clinics: Clinics, including primary care and specialist centers, are also important points of distribution. These facilities often provide convenient access to vaccines.

  3. Pharmacies: Retail pharmacies are emerging as a significant distribution channel, particularly for individuals who prefer getting vaccinated outside of healthcare facilities. Pharmacies offer convenience and accessibility for many consumers.

By Region

  1. North America: North America dominates the shingles vaccine market due to high vaccine awareness, strong healthcare infrastructure, and government-backed vaccination programs. The U.S. and Canada are major contributors to this region's market share.

  2. Europe: Europe also holds a significant share of the market, driven by high vaccination rates, healthcare policies encouraging vaccination, and an aging population.

  3. East Asia: East Asia, with its rapidly aging population and increasing healthcare access, presents substantial growth opportunities for shingles vaccines.

  4. South Asia and Oceania: While the market in South Asia and Oceania is still developing, the increasing availability of vaccines and awareness campaigns are expected to drive growth in the coming years.

  5. Latin America: Latin America is expected to witness steady growth, as countries in this region are strengthening their healthcare systems and vaccination programs.

  6. Middle East and Africa: The market in the Middle East and Africa is still in its nascent stages but presents significant opportunities due to increasing healthcare infrastructure and rising demand for vaccines.

Read More: https://www.persistencemarketresearch.com/market-research/shingles-vaccine-market.asp 

Competitive Landscape

The global shingles vaccine market is highly competitive, with several major players dominating the market. These include:

  • GlaxoSmithKline plc.: A leading player in the vaccine market, GSK is known for its recombinant vaccine Shingrix, which has become the preferred choice for shingles prevention.

  • Merck & Co., Inc.: Merck's Zostavax was one of the first vaccines to be approved for shingles, and although it has been largely replaced by Shingrix, Merck remains a key player in the vaccine market.

  • SK Chemicals: SK Chemicals is expanding its presence in the global shingles vaccine market with its offerings in various regions.

  • Green Cross Corp: A South Korean company that has been active in developing vaccines for infectious diseases, including shingles.

  • Geneone Life Science: A biotechnology firm involved in the development of vaccines, including for shingles, Geneone is focused on innovative vaccine solutions.

  • Vaccitech, CanSinoBIO, Cipla Inc., Pfizer Inc.: These companies are also significant contributors to the market, each focusing on advancing vaccine technology and expanding their market share.

Conclusion and Future Outlook

The shingles vaccine market is poised for significant growth over the next several years, driven by a combination of demographic shifts, technological advancements, and increased public awareness. As the global population ages, the demand for effective vaccines will continue to rise, and with it, the market for shingles vaccines. Companies that can innovate and address the challenges of vaccine access and affordability will be well-positioned to capitalize on this growth. Moving forward, strategic partnerships, government initiatives, and continuous advancements in vaccine development will play a crucial role in shaping the future of the shingles vaccine market.

Comments

Post a Comment

Popular posts from this blog

Legionella Testing Market Expansion Supported by Rising Awareness of Legionnaires’ Disease

Image
  The global legionella testing market , which is currently valued at USD 322.4 million in 2026, is projected to grow substantially, reaching USD 547.8 million by 2033. This robust growth represents a compound annual growth rate (CAGR) of 7.9% from 2026 to 2033. Several factors, including the rising incidence of Legionnaires' disease and increasing government regulations around water safety management, are fueling this expansion. As the prevalence of waterborne diseases like Legionnaires' disease escalates globally, the demand for reliable and efficient testing methods continues to rise, creating significant opportunities within the market. Market Dynamics: Drivers and Challenges Driver: Rising Incidence of Legionnaires' Disease and Aging Infrastructure One of the primary drivers of the legionella testing market’s growth is the increasing number of Legionnaires' disease cases globally. According to the Centers for Disease Control and Prevention (CDC), in the United Sta...
Read more

Antibody Testing Market Expands Amid Rising Demand for Accurate COVID-19 Screening Solutions

 The global antibody testing market is set for substantial expansion over the next decade, driven by growing demand for accurate diagnostic tools, increasing prevalence of infectious and chronic diseases, and significant advancements in immunodiagnostic technologies. According to the latest industry analysis, the global antibody testing market size is expected to be valued at US$9.4 billion in 2025 and projected to reach US$16 billion by 2032 , growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2025 to 2032. Market Overview Antibody testing, also known as serology testing, plays a crucial role in detecting the presence of antibodies in the blood, indicating an immune response to infections, vaccines, or autoimmune disorders. Over the past few years, the market has witnessed accelerated growth due to the increased demand for diagnostic tests following the COVID-19 pandemic. The rise in awareness regarding preventive healthcare, increasing healt...
Read more

UAE Health Check-up Market Set for Robust Growth Driven by Preventive Healthcare Initiatives

Image
  The UAE health check-up market is on a strong growth trajectory, projected to reach US$ 113.8 million by 2032, up from US$ 77.0 million in 2025, reflecting a compound annual growth rate (CAGR) of around 5.0% during the forecast period. This growth reflects a notable transformation in the UAE’s healthcare landscape, where residents are increasingly shifting from reactive treatment approaches to proactive, preventive care. Regular health check-ups are now being recognized as essential components of personal well-being rather than optional services. The growing focus on lifestyle disease management, government-led health campaigns, mandatory screenings for residency and employment, and innovative diagnostic technologies are driving this trend, particularly in urban hubs like Abu Dhabi and Dubai. Key Industry Highlights General health check-ups are expected to hold a dominant share in 2025, driven by the adoption of wellness programs among corporates. Companies are increasingly inco...
Read more